Nearly 40 years after HIV was first identified, the virus continues its devastating march across the globe. Today, 38 million people live with HIV, and each year brings 1.5 million new infections and ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...

Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Ten years ago, the Indiana community of Austin made headlines for its historic HIV outbreak brought on by intravenous drug ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...

"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.

A pioneering opt-out testing programme for HIV, hepatitis B, and hepatitis C in NHS emergency departments has identified thousan ...